Day One Announces Proposed Public Offering of Common Shares

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages living with Threatening Diseases, today announced that it has launched a subscribed public offering of $125.0 million shares of its common stock. All common shares are offered by Day One. In addition, Day One intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of common stock at the public offering price, less discounts and underwriting fees. . The proposed offer is subject to market and other conditions, and there can be no assurance as to whether or not the offer will be completed, or as to the actual size or terms of the offer.

JP Morgan, Cowen and Piper Sandler are acting as joint bookrunners for the proposed offering. Wedbush PacGrow is acting as lead manager of the proposed offering.

The securities are being offered by Day One pursuant to a registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and the accompanying base prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus may also be obtained, when available, from: JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by phone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by phone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by phone at (800) 747-3924, or by email at prospectus@psc.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. prior to registration or qualification. under the securities laws of such state or territory.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes that when it comes to pediatric cancer, we can do better. We put children first and develop targeted therapies that meet their needs. Day One was founded to address a critical unmet need: the glaring lack of therapeutic development in pediatric cancer. The company name was inspired by “The Day One Talk” doctors have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to rethink cancer drug development and redefine what is possible for all people with cancer, regardless of age, from day one.

Day One partners with leading clinical oncologists, families and scientists to identify, acquire and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, brain-penetrating, highly selective pan-RAF kinase type II inhibitor. The Company’s pipeline also includes pimasertib, an experimental, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management’s current beliefs and expectations and include, but are not limited to, limit, statements regarding the timing, size and anticipated gross proceeds of the offering, the satisfaction of customary closing conditions relating to the offer and sale of securities, the grant to underwriters of an option to purchase of additional shares and the ability of Day One to complete the offer. All statements other than statements of historical fact are statements that could be considered forward-looking statements. Although Day One believes that the expectations reflected in these forward-looking statements are reasonable, it cannot guarantee that these expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that could cause Day One’s actual operations or results to differ materially from those expressed in any forward-looking statement, including, without limitation, risks and uncertainties relating to market conditions and satisfaction of closing conditions. related to the proposed public offering, and the risks and uncertainties described under “Risk Factors” in documents that Day One files from time to time with the SEC, including Day One’s Quarterly Report on Form 10- Q filed with the SEC on May 12, 2022, the preliminary prospectus supplement relating to this offering, and its future periodic reports to be filed with the SEC. These forward-looking statements speak only as of the date of this press release, and Day One undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum
hans@lifesciaadvisors.com

About Barbara J. Ross

Check Also

Arcellx Announces Closing of Increased Public Offering of Common Shares and Full Exercise of Option to Purchase Additional Shares by Underwriters

REDWOOD CITY, CA., June 21, 2022 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company …